Drug Profile
Research programme: type 2 diabetes therapeutics - Spencer Pharmaceutical
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Ecole Polytechnique
- Developer Spencer Pharmaceutical
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Type-2-diabetes-mellitus in USA
- 10 Mar 2011 Early research in Type-2 diabetes mellitus in USA (unspecified route)